Invectys is a biopharmaceutical company founded in 2010 and focusing on the development of innovative immunotherapy approaches to treat cancers. The company develops a novel approach to mobilising and restoring the anti-tumour capacity of the immune system of cancer patients. This allows virtually all cancers to be targeted. Invectys focuses its efforts on two highly prevalent tumour antigens: the nearly-universal tumour antigen telomerase that is critical to uncontrolled cell growth, and the HLA-G immune checkpoint expressed in over 50% of cancers.

https://www.invectys.com/